

Psychedelic Inspired Medicines

April 2021

NEO
MMED

NASDAQ
MNMD

DE
MMQ



Disclaimer

Market and Industry Data

This presentation by Mind Medicine (MindMed) Inc. (the "Presentation") includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

CAUTIONARY NOTE ON FORWARD LOOKING INFORMATION

This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information") with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "will", "projects", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions "may", "could", "would", "might" or "will" be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approval, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed not electing to proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful.

To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed's financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted.

Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein.

Leadership Team - Diverse & Extensive Biotech Experience

JR Rahn

Co-Founder, Director & CEO



JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines.

He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JR worked in market expansion and operations at Uber.

Dr. Miri Halperin Wernli, PhD

Executive President; Board Director; Head of Development Pipeline Programs & Digital Medicine



Dr. Halperin Wernli co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2016. Prior to founding Creso Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.

Robert Barrow

Chief Development Officer



Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Dan Karlin, MD MA

Chief Medical Officer



Dan previously co-founded HealthMode in 2018 and served as CEO. Before that, he built and led clinical, informatics, and regulatory strategy for Pfizer's Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Before that, he was the founder and Chief Medical Officer at Column Health in 2013, a leading technology-enabled psychiatry and addiction practice. He's a strategic Advisor, Otsuka Pharmaceuticals, Click Therapeutics, Syntegra, Recovery Delivered, NightWare. He is also a founding Advisor of the Digital Biomarkers Journal, founder and Board Member, Digital Medicine Society (DiMe), and is on committee Leadership Digital Drug Development Tools at Critical Path Alzheimer's Disease, MJFF, and Mental Health IT at the APA. Dan is board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is also an assistant Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

Carol Nast

Chief Operating Officer



Carol has spent her career in executive level positions with large multinational companies and early stage companies in the medical industry. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has lead successfully the development and commercialization of over 100 products. Carol was COO at NuGen, a genomics company, and served in executive level positions at Inhale Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals,) BioRad and Pfizer. Her passion is the successful launch and adoption of breakthrough products in emerging markets that have significant impact by solving a vexing challenge.

Bradford Cross

Chief Technology Officer



Bradford previously co-founded HealthMode in 2018, currently serves as its CTO. Career entrepreneur and investor with 15+ years at the intersection of AI and startups, and finance. Founded Vertical AI startups in 2016-18 in highly regulated industries including clinical trials, real estate appraisal and lending, cyber insurance, and anti-money laundering. Founded Prismatic in 2012, which powered part of LinkedIn's newsfeed as of 2015. Machine learning for personalization and content classification. Founded DCVC in 2011, which has grown into a \$2B+ leading deep tech VC investing heavily at the intersection of computation and bio and spinning up dedicated DCVC bio fund. Founded Flightcaster in 2009, first AI Startup in YCombinator. Machine learning for predicting the real time state of the global air traffic network. He previously worked in distributed systems at Google 2007-2009. Brad earned degrees in Computer Science and Finance at Virginia Tech, and Mathematics at Berkeley.

MindMed Has Pioneered a New Asset Class

Psychedelic Inspired Medicine is The Latest Advancement in Biotech

\$4.7B

Global annual **Anxiety drug sales**¹

\$9.5B

Global annual **ADHD drug sales**¹

\$5.8B

Global annual **Anti-Addiction drug sales**¹

\$9.6B

Global annual **Depression drug sales**¹

Corporate Strategy & Thesis:

- Patients deserve more effective medicine and therapies for mental health and addiction
- Most diversified & extensive psychedelic development pipeline in the psychedelics industry
- Aquisitive clinical trial approach is cost efficiency and effective
- Unique focus on all stages of development and delivery - From discovery to insurance

Institutional Market Momentum:

- Government: DARPA (\$27 million USD)
- Big Pharma: Johnson & Johnson Phase 1 to Approval (Spravato)
- Universities: Johns Hopkins University, University Hospital Basel, NYU Langone School of Medicine, Maastricht University



Spravato
(esketamine) 
nasal spray

\$1.7 Billion Comparable Drug Value²



Strict Regulatory Adherence & FDA Process:

- Open IND - (Investigational New Drug)
- Approval by the Institutional Review Board
- Conduct research under Schedule 1 License from DEA (if compound is schedule 1)
- Complete usual clinical trial process for approval

Breakthrough Therapy Designation (BTD):

- Others have already received three designations in psychedelics

Mental Health: The \$16 Trillion Elephant in the Room⁸

Global Mental Health Cost Expected to total \$16 trillion through 2030

Anxiety:

284 M

Globally suffer from anxiety³

→

\$1 Trillion

per year in lost global productivity due to anxiety⁴

Addiction:

300 M

Amount of Annual Opioid Prescriptions in the US⁵

→

\$2.5 Trillion

Cost of the Opioid Epidemic to the United States economy over four years⁶

ADHD:

16 M


US Adult ADHD Sufferers⁷

→

\$194 Billion

Lost productivity Annually in the US⁸

CMS Spend On OUD & Withdrawal Drugs (\$Millions) USD




Source: US Centers for Medicare & Medicaid Services

Current Solutions Are Not Working

Anxiety:

+67%

Increase in benzodiazepine prescriptions (1996-2013)¹³




36%

of patients actually seek treatment¹⁴

Addiction:

+395%

Increase in Overdose Deaths Involving Prescription Opioids 1999-2018⁹




88%

of patients relapse when buprenorphine/naloxone therapy is tapered¹⁰

ADHD:

+123%

Increase in ADHD prevalence¹¹




89.1%

Individuals not receiving treatment¹²

LSD May be a Safer Alternative

Benzodiazpines are 2x more harmful than LSD¹⁵



Emergency Room visits involving illicit drugs, 2011¹⁶

Substance	ER Visits
Cocaine	505,224
Heroin	258,482
Cannabinoids	479,560
Amphetamines	159,840
LSD	4,819
% of Total ER Visits	<u>0.34% of ER visits</u>

A New Treatment Paradigm

Product Delivery Categories



Non-Hallucinogenic

- LSD Microdosing for ADHD
- 18-MC for Addiction

HOW IT'S DONE

Derived from psychedelics, negligible hallucination effect

HOW IT'S DELIVERED

Doctor prescription

Pharmacy pickup and take-home



Hallucinogenic

- LSD Experiential Therapy for Anxiety
- LSD Experiential for Cluster Headaches

HOW IT'S DONE

A high dose or "experiential" dose of psychedelics

HOW IT'S DELIVERED

Overseen by therapist & doctor

In-clinic treatment only

MindMed Is Collaborating With Leading Psychedelic Researchers

Clinical Researchers With Psychedelic Research Experience Are Rate Limiting Factors

University Hospital Basel's Liechi Lab



- Acquired 10+ years of valuable research & data
- Most valuable LSD data for drug development
- 17 completed or ongoing clinical trials of psychedelics

Maastricht University



- Leading research experts for microdosing of psychedelics
- Phase 2a Clinical Trial - Adult ADHD



Professor Dr. Matthias Liechi, PhD & M.D.

Leader of Liechi Lab at University Hospital Basel



Dr. Kim Kuypers PhD



Dr. Peter Gasser M.D.

"Meet the Only Doctor in the World Legally Allowed to Use LSD to Treat Patients" - VICE



Matthew W. Johnson, PhD

Leading expert at Johns Hopkins University Center for Psychedelic Research

A Process To Build The New Treatment Paradigm



Broadest & Most Diversified Pipeline of Psychedelic Drugs in Clinical Development and R&D

Pipeline Diversification Offers Access To Full Spectrum Of Psychedelic Inspired Medicines



Develop: Commercial Drug Trials

MindMed Acquired Phase 2 Trial, Now Advancing as Phase 2b With FDA

Using Phase 2 Trial To Jumpstart a Potential Phase 2b LSD Trial For Anxiety Disorder Est. Q4 2021


Value through clinical trial acquisitions:



Acquired ongoing Phase 2 Anxiety clinical trial from UHB led by [Dr. Peter Gasser](#) & Dr. Matthias Liechti



LSD Development Plan:



Based on industry averages, this saves roughly **\$8.4 to \$26.2 million** in non-dilutive financing costs and 4+ years of time¹⁷

Currently preparing to open the IND with a Phase 2 Study

Plan to file IND Q3 2021

Develop: LSD Microdosing Phase 2a Clinical Trial

Proof of Concept Using Sub-perceptual Amounts of LSD (Microdose)

Dr. Kim Kuypers will serve as Principal Investigator for Maastricht site



Dr. Matthias Liechti will serve as Principal Investigator for the Basel site



Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:

- Increase focus
- Decrease anxiety
- Increase creativity
- Improve mood



Clinical Trial Progress and Details:

- Phase 2a anticipated to begin in Q3 2021 in Europe
- Low dose LSD (20 mcg) compared with a placebo administered for 6 weeks

Locations:


- Maastricht (Netherlands)



*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed's control


18-MC : Creating the Antibiotic of Addiction

Addressing Addiction as a Brain Disease



Develop: 18-MC Development Plan

Finishing Phase 1 MAD/ SAD & Preparing Phase 2a Opioid Withdrawal Q3 2021



Phase 2a Trial Design:

Single Ascending Dose: Ongoing	Investigating the efficacy of 18-MC in mitigating the symptoms of opioid withdrawal	Three cohorts: High Dose Low Dose Placebo	Participants will be treated for 8-days while undergoing opioid detox	32 patients per cohort	Management of withdrawal symptoms compared with placebo	Proportion who complete the trial compared with placebo
Multiple Ascending Dose: Ongoing						

*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed's control

Discover

Early Stage R&D and Psychedelic Drug Discovery


Acquired World Leading Clinical Trial Data Sets On Psychedelics

University Hospital Basel Collaboration

MindMed is working with the Liechti Lab to research and develop next-gen therapies, compounds, and dosing technologies


We have an exclusive license for DMT, MDMA, LSD and Psilocybin

13 Trials Completed
4 Ongoing




DMT


Active ingredient in
Ayahuasca



MDMA



PSILOCYBIN



LSD



 **Universitätsspital
Basel**

Department of
Biomedicine

Invaluable & Protectable IP


MindMed is Building an Expansive Patent Portfolio

Each stage of the process will generate an evolving family of intellectual property including:

- Composition of matter and methods of manufacturing
- Claims covering a library of homologues
- New indications
- Formulations
- Digital Methods & Products
- AI and ML algorithms and models
- Drug + drug combination therapies
- Drug + device combination therapies
- Dosing protocols

Patents on known substances such as LSD can be obtained based on:

- A new use or disease indication
- Unique treatment modality (dose or regimen)
- Finding unique chemical properties (polymorph, salt form, etc.) that:
 - May work better than the known substance;
 - May have better biopharmaceutical properties; or
 - Include novel combinations of known substances



IP Example : Putting the Patient & Therapist in Control

Potential to Improve the Safety & Patient Experience

LSD Neutralizer:



A substance with the expected ability to abort the hallucinogenic effects of LSD within 20 to 30 minutes

Purpose & Use Cases

- Shorten and stop LSD trips while giving the patient and therapist control
- End experiential therapy in progress
- Abuse deterrence
- Researching how the substance might be time-released within another compound

Intellectual Property Status:

- MindMed and University Hospital Basel have filed a patent application in the US, which preserves worldwide rights



Provide therapists and medical professionals with the tools to control LSD effects in a clinical setting

Discover: MindMed & MindShift Create the Discovery Division


Developing Novel Compounds Derived from Psychedelic Substances or Synthesized from Existing Compounds

Engineering a portfolio of compounds & formulations that are expected to demonstrate variations in:

- Onset of action
- Duration
- Potency
- Safety
- Receptor Selectivity

The Novel Compounds (or Chemical Structures) will be:

- Derivatives of existing compounds
- Potentially enhanced versions of established and classic psychedelic compounds
- Compounds with expected combined psychedelic-empathogenic effect profiles



MindShift is expected to enable MindMed to bring a new line of psychedelic compounds into trials

Discover: Groundbreaking LSD Microdosing Study Using Digital Clinical Markers


Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

Combining LSD & Digital to Understand Effects On:

- BDNF plasma levels
- Sleep measures
- Quality of life
- Mood
- Cognitive performance
- Immune system response

World-Leading Researchers

- Led by [Dr. Kim Kuypers](#)



Deploy

Psychedelic Drug Delivery

Deploy: Investing in the Future of Medicine with NYU Langone Medical Center

Building critical infrastructure for bridging access to large groups of mental health professionals

Long-term Commitment to Solving Mental Health Issues:

- MindMed is committing \$5 million over a five-year period
- Initial focus on substance use disorders including opioid addiction and alcoholism
- Catalyze efforts to recruit and train more psychiatrists and clinical investigators

Managed by NYU's Seasoned Clinical Experts



Michael Bogenschutz, M.D.

Primary investigator leading the effort towards FDA approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder



Stephen Ross, M.D.

World leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist



NYU Langone Health and NYU
Grossman School of Medicine


Introducing Albert: The Digital Medicine Division for Psychedelics

The Future of Modern Medicine Relies on Measurement

More than 60% of all counties in the US - including 80% of all rural counties do not have access to a psychiatrist¹⁹

Measure	Analyze	Commercialize
Measurements use to improve efficiency & efficacy of clinical development and clinical care	Focused on medical meaning & regulatory acceptance	Enables remote medicine, personalized patient care, & clinical care optimization

A data driven, technology integrated, patient centered engine for efficient discovery, development, and deployment of psychedelic inspired medicines and digital companion treatments



Immediate Uses & Commercial Impact of the Albert Division

Technology Integration Can Enhance All Phases of the Clinical Paradigm

Areas of Immediate Impact:

- Clinical Trials
- Disease Diagnosis
- Remote Patient Monitoring
- Treatment Matching & Selection
- Relapse Prevention
- Adherence Monitoring

COVID-19 has precipitated a wider scale need for adoption of:

- Telehealth and remote care modalities
- Remote clinical trials

Telehealth visits up +1000% during COVID-19 pandemic¹⁸


New parterships driven by software

Lead to near-term revenue




Near Term Inflection Points For MMED

MindMed Is Capitalizing On Opportunity



Near Term Inflection Points Timeline:



NASDAQ: MNMD // NEO: MMED // DE: MMQ

First Publicly Listed Psychedelic Biotech Company

Share Ownership (As of 2/16/2021)		
Executive Team/Directors/Insiders	74,985,214	17.3%
Non-insider shares	310,098,149	71.4%
Equity Incentive Plan (Issued)	23,742,427	5.5%
Outstanding Warrants	25,599,807	5.9%
Total (Fully diluted)	434,425,597	100%
Number of Shareholders	200,000+	

\$204M

USD Raised since inception
(including warrants)

Strong investor backing

- Seed Round Aug '19: \$6m USD
- Pre-Public Feb '20: \$24m USD
- Bought Deal Financing May '20: \$10m USD
- Bought Deal Financing Oct '20: \$22m USD
- Bought Deal Financing Dec '20: \$27m USD
- Bought Deal Financing Jan '21: \$72m USD
- Bought Deal Financing March '21: \$15.4m USD



Market Cap USD: \$1.6 billion April 27th (\$4.69 price per share)

Market Cap CAD: \$1.9 billion April 27th (\$5.84 price per share)


Board of Directors

JR Rahn

Co-Founder, Director & CEO



JR Rahn is a former Silicon Valley tech executive. JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded.



Bruce Linton

Director, Chair of Compensation, Governance and Nominating Committee



Bruce Linton is an activist Investor with SLANG Worldwide Inc. (CSE:SLNG). Activist Investor with OG DNA Genetics Inc Founder and Former Chairman and CEO of Canopy Growth Corporation (CGC/WEED). Bruce chairs the board's Compensation, Governance and Nominating Committee.



Stephen L. Hurst, JD

Co-Founder and Director



Stephen Hurst has more than thirty-five years' experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.



Brigid Makes

Director, Chair of Audit Committee



Brigid Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhale Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board's Audit Committee.



Dr. Miri Halperin, PhD

President, Director



Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.



Perry Dellelce

Chairman of the Board of Directors



Perry Dellelce is a managing partner of Wildeboer Dellelce LLP. He also serves as chair of the NEO Exchange, Canada's newest stock exchange. Board Member of Mount Logan Capital Inc. and Lendified Inc.



A Track Record of Success Across Several Industries

Jeanne Bonelle

EVP, Technical Operations



Jeanne has established quality systems within the developmental phase for a wide range of products, including Senior Director of Quality Assurance at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.); Director of Quality Assurance at Cholestech Inc. (now Alere Inc.); Manager of Quality Assurance at BioTrack, (now a subsidiary of Roche Diagnostics GmbH); Manager of Quality Assurance at BioResponse Inc. (now Baxter Health Care).

Dave Guebert

Chief Financial Officer



Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry.

Carole Abel

Vice President Programs & Europe



Carole has over 23 years of experience in multidisciplinary environments, including 15 years in the pharma industry in Switzerland (Actelion Pharmaceuticals and Creso Pharma). She has been successfully leading cross-functional teams and directing groups in different areas: operations, project management, and process improvements. Over the last few years, Carole has been instrumental in the preparation and coordination of corporate audits and due diligence activities.

Collin Gage

Vice President of Corporate Development



Collin began his career at Point72 Asset Management. From there, he worked at the Genjiko Family Office. While at Genjiko he was responsible for selecting and researching alternative investments, expansionary efforts, and capital management. Genjiko is the family office of a former Fortune 50 C-Level executive. During this period, Collin also helped co-found a biotech focused venture capital fund called Presight Capital.

Madeline Feldman

Director of Operations & Administration



Madeline has a background supporting startups through corporate innovation and investor relations, fundraising for venture capital funds and non-profit organizations, and building out operational departments in various industries. She has a love for performing arts and works with artists in creating and producing stage shows for major venues and resorts.

Nico Forte

Senior Director, Business Operations and Development



Nico has more than twenty-five years of marketing and business development experience primarily in the biopharma and medical device industries. His background includes B2B agency marketing and communication work for Bristol-Myers and Mead Johnson Oncology divisions as well as business development roles for Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.).

Donald Gehlert, PhD

Chief Scientific Officer



Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology. During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule therapies. He also participated on Phase I and Phase II clinical development teams that designed and delivered translational proof of concept studies in the areas of ADHD, obesity, AUD, depression, pain and migraine. He is a co-author on 182 publications and a co-inventor on 15 issued and pending patents.

Shahera St. John

Vice President, Programs



Shahera has nearly 20 years of project management experience. As an independent consultant, Ms. St. John supported companies of all sizes from start-up to Fortune 100 companies in biotech, pharma, and medical device. She has worked with various sized teams to help advance programs from early research/R&D through all phases of development, including Phase 3 and commercialization. Ms. St. John obtained her degree in Molecular, Cellular, and Development Biology from the University of California, Los Angeles.

Daniel E. Levy, Ph.D.

Vice President, CMC



Dr. Levy is an experienced organic/medicinal chemist having contributed to the design of novel therapeutic agents targeting cardiovascular disease, cancer, inflammatory and CNS disorders. In almost 30 years of contributing to the biopharmaceutical industry, Dr. Levy led interdisciplinary teams focused on kinase inhibitors, GPCR antagonists, matrix metalloproteinase inhibitors and cell adhesion molecules. His work is documented in almost 30 peer-reviewed publications and over 24 issued/published United States patents.

Rachann McKnight

Director, Business Process



Rachann is a visionary leader, executor, and manager with experience directing startup operations in a growth-minded direction. She has a history of helping early-stage companies scale, building out high performing teams and business processes, and executing large-scale corporate events — including conferences with 10k+ attendees. Rachann is passionate about companies whose primary missions are to use their collective power for good and has lead numerous successful diversity and inclusion efforts in support of that collective good.


Scientific Advisory Board - Deep & Relevant Expertise



Stanley D. Glick, PhD
Scientific Advisor 18-MC



John Rotrosen, MD
Professor of Psychiatry NYU Langone



Kenneth Alper, MD
*Clinical Associate Professor of
Psychiatry and Neurology*



Sarah McCallum, PhD
*Associate Professor of Neuroscience
and Experimental Therapeutics*



Matthew W. Johnson, Ph.D
Professor at Johns Hopkins



Jed Rose, PhD
*Professor in Psychiatry and Behavioral
Sciences at Duke University*



John Blacker, PhD
*Professor of Process Chemistry,
University of Leeds*



Natalie Wheeler, PhD
*Medical Science Liaison with Dova
Pharmaceuticals*



Eric Edwards, MD, PhD
*Co-founder and Member, Board of
Directors at Kaleo, Inc.*



Mindmed in the News

THE WALL STREET JOURNAL.

"Psychedelics-Drug Startup Raises \$24 Million Ahead of IPO." February 27, 2020

Bloomberg

"Its market capitalization of over C\$1 billion puts the company ahead of at least eight companies in Canada's benchmark S&P/TSX Composite Index, according to data compiled by Bloomberg." December 9, 2020



"A startup that wants to use psychedelics to treat addiction just raised \$6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower" Sep 30, 2019

FASTCOMPANY

*"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?" -Kevin O' Leary
December 9, 2019*

THE NEW YORKER

"New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center." October 12, 2020

FORTUNE

"Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution." February 17, 2020

Forbes

"Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing" September 25, 2020

TOWN&COUNTRY

"The evidence for psychedelics as medicine is far greater than that for CBD, which companies are selling to relieve ills from Parkinson's to Crohn's." April 13, 2020



"MindMed named one of 36 startups that could change the world" December 17, 2019

Sources

1. IQVIA. (2021, February). IQVIA Global Annual Sales Report.
2. Goldman Sachs. (2019, May). Americas Healthcare: Pharmaceuticals.
3. Ritchie, H. (2018, January 20). Mental Health. Our World in Data. <https://ourworldindata.org/mental-health#:~:text=Globally%20an%20estimated%20284%20million,experience%20anxiety%20disorders%20than%20men>.
4. Mental health in the workplace. (2021). WHO. <https://www.who.int/teams/mental-health-and-substance-use/mental-health-in-the-workplace>
5. United Nations International Narcotics Control Board. Estimated World Requirements for 2017. Statistics for 2015. Accessed September 20, 2018.
6. timothy.esteves. (2019, November 12). The Opioid Epidemic Cost the U.S. Economy \$2.5 Trillion in 4 Years. American Addiction Centers. <https://americanaddictioncenters.org/blog/opioid-epidemic-cost-the-economy-2-5-trillion>
7. Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
8. Patel, V. P. (2016). The Lancet Commission on global mental health and sustainable development. The Lancet Commission, VOLUME 392(ISSUE 10157), 1553–1598. [https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(18\)31612-X.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(18)31612-X.pdf)
9. Overdose Death Rates. (2020, August 25). National Institute on Drug Abuse. [https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20prescription,\(Source%3A%20CDC%20WONDER\)](https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20prescription,(Source%3A%20CDC%20WONDER)).
10. Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Gourevitch, M. N., Haller, D. L., Hasson, A. L., Huang, Z., Jacobs, P., Kosinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., Sonne, S. C., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Archives of general psychiatry, 68(12), 1238–1246. <https://doi.org/10.1001/archgenpsychiatry.2011.121>
11. Chung W, Jiang S, Paksarian D, et al. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. JAMA Netw Open. 2019;2(11):e1914344. doi:10.1001/jamanetworkopen.2019.14344
12. Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Connors, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., Spencer, T., Ustun, T. B., Walters, E. E., & Zaslavsky, A. M. (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. The American journal of psychiatry, 163(4), 716–723. <https://doi.org/10.1176/ajp.2006.163.4.716>
13. Marcus A. Bachhuber, Sean Hennessy, Chinazo O. Cunningham, Joanna L. Starrels, "Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013", American Journal of Public Health 106, no. 4 (April 1, 2016): pp. 686-688.
14. Facts & Statistics | Anxiety and Depression Association of America, ADAA. (2020). ADAA. <https://adaa.org/about-adaa/press-room/facts-statistics>
15. Nutt, David & King, Leslie & Phillips, Lawrence. (2010). Drug harms in the UK: A multi-criterion decision analysis. Lancet. 376.
16. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. (2013, May). Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. <https://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED.pdf>
17. Sertkaya, A., Wong, H. H., Jessup, A., & Beleche, T. (2016). Key cost drivers of pharmaceutical clinical trials in the United States. Clinical trials (London, England), 13(2), 117–126. <https://doi.org/10.1177/1740774515625964>
18. Office of Public and Intergovernmental Affairs. (2020). VA.gov | Veterans Affairs. U.S. Department of Veterans Affairs. <https://www.va.gov/opa/pressrel/pressrelease.cfm?id=5467>
19. New American Economy. (2017). The Silent Shortage. http://www.newamericaneconomy.org/wp-content/uploads/2017/10/NAE_PsychiatristShortage_V6-1.pdf

